Home›Linagliptin

Linagliptin

Also known as: Linagliptin

Dipeptidyl Peptidase 4 InhibitorDipeptidyl Peptidase 4 Inhibitors

Route: Oral

3 interactions on record

Linagliptin has 3 known drug interactions based on U.S. FDA drug labeling data. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Insulin Human, Rifampin, Sulfonylurea. Patients taking Linagliptin should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 3
Major: 3

Major (3)

Linagliptin + Insulin Human— Coadministration increases risk of hypoglycemia. Lower dosages of insulin may be required when used with linagliptin.
Linagliptin + Rifampin— Rifampin decreases linagliptin exposure and may reduce efficacy of TRADJENTA. Alternative treatments strongly recommende…
Linagliptin + Sulfonylurea— Insulin secretagogue that increases hypoglycemia risk when combined with linagliptin. Lower dosages of sulfonylurea may …

Linagliptin + Insulin Human⚠️Major

Coadministration increases risk of hypoglycemia. Lower dosages of insulin may be required when used with linagliptin.

Linagliptin + Rifampin⚠️Major

Rifampin decreases linagliptin exposure and may reduce efficacy of TRADJENTA. Alternative treatments strongly recommended.

Linagliptin + Sulfonylurea⚠️Major

Insulin secretagogue that increases hypoglycemia risk when combined with linagliptin. Lower dosages of sulfonylurea may be required.

Contraindications

4 CONTRAINDICATIONS Linagliptin is contraindicated in patients with a history of a hypersensitivity reaction to linagliptin, such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial Linagliptin is contraindicated in patients with hypersensitivity to linagliptin or any of the excipients in linagliptin tablets, reactions such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity have occurred [see Warnings and Precautions (5.4) and Adverse Reactions (6) ] . Hypersensitivity to linagliptin or any of the excipients in linagliptin tablets. ( 4 , 5.4 )

Pregnancy & Breastfeeding

8.1 Pregnancy Risk Summary The limited data with TRADJENTA use in pregnant women are not sufficient to inform of drug-associated risk for major birth defects and miscarriage. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy [see Clinical Considerations ]. In animal reproduction studies, no adverse developmental effects were observed when linagliptin was administered to pregnant rats during the period of organogenesis at doses similar to the maximum recommended clinical dose, based on exposure [see Data ] . The estimated background risk of major birth defects is 6% to 10% in women with pre-gestational diabetes with a HbA1c >7 and has been reported to be as high as 20% to 25% in women with HbA1c >10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity. Data Animal Data No adverse developmental outcome was observed when linagliptin was administered to pregnant Wistar Han rats and Himalayan rabbits during the period of organogenesis at doses up to 240 mg/kg/day and 150 mg/kg/day, respectively. These doses represent approximately 943-times (rats) and 1,943-times (rabbits) the 5 mg maximum clinical dose, based on exposure. No adverse functional, behavioral, or reproductive outcome was observed in offspring following administration of linagliptin to Wistar Han rats from gestation day 6 to lactation day 21 at a dose 49-times the maximum recommended

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.